BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29943377)

  • 1. Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method.
    Lee CF; Ng R; Luo N; Cheung YB
    Appl Health Econ Health Policy; 2018 Oct; 16(5):685-695. PubMed ID: 29943377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mean Rank, Equipercentile, and Regression Mapping of World Health Organization Quality of Life Brief (WHOQOL-BREF) to EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities.
    Wee HL; Yeo KK; Chong KJ; Khoo EYH; Cheung YB
    Med Decis Making; 2018 Apr; 38(3):319-333. PubMed ID: 29587045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
    Thompson NR; Lapin BR; Katzan IL
    Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index.
    Shi Y; Thompson J; Walker AS; Paton NI; Cheung YB;
    Health Qual Life Outcomes; 2019 May; 17(1):83. PubMed ID: 31077251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
    Jiang L; Zhou H; Yang Q; Luo X; Huang D
    Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group's 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population.
    Cheung YB; Luo N; Ng R; Lee CF
    Health Qual Life Outcomes; 2014 Dec; 12():180. PubMed ID: 25495840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
    Huang D; Peng J; Chen N; Yang Q; Jiang L
    Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets.
    Lamu AN; Chen G; Gamst-Klaussen T; Olsen JA
    Qual Life Res; 2018 Jul; 27(7):1801-1814. PubMed ID: 29569014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
    Su J; Liu T; Li S; Zhao Y; Kuang Y
    J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
    Kaambwa B; Ratcliffe J
    Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does linear equating improve prediction in mapping? Crosswalking MacNew onto EQ-5D-5L value sets.
    Lamu AN
    Eur J Health Econ; 2020 Aug; 21(6):903-915. PubMed ID: 32300999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
    Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
    Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?
    Luo N; Cheung YB; Ng R; Lee CF
    Health Qual Life Outcomes; 2015 Oct; 13():166. PubMed ID: 26438167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.